Adjuvance Overview

  • Founded
  • 2009

  • Status
  • Out of Business

  • Employees
  • 18

  • Latest Deal Type
  • Out of Business

Adjuvance General Information


Developer of a biopharmaceutical platform designed to improve health and save lives through the development of vaccine adjuvant. The company's platform is based on SAPONEX products that are critical components to many vaccines for multiple indications in infectious disease, oncology, neurobiology, substance abuse, and allergy, enabling patients to improve their immune systems.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 1225 L Street
  • Suite 600
  • Lincoln, NE 68508
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adjuvance Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Out of Business 20-Apr-2022 000.00 Completed Out of Business
6. Grant 19-May-2020 00.000 000.00 Completed Pre-Clinical Trials
5. Later Stage VC (Series A1) 29-Jan-2020 0000 000.00 0000 Completed Pre-Clinical Trials
4. Grant 01-Jan-2020 00000 00.00 Completed Pre-Clinical Trials
3. Seed Round 29-Aug-2019 00.00 00.00 Completed Pre-Clinical Trials
2. Grant 01-Mar-2017 $1.5M Completed Pre-Clinical Trials
1. Grant 01-Jan-2017 $448K Completed Pre-Clinical Trials
To view Adjuvance’s complete valuation and funding history, request access »

Adjuvance Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A-2 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Adjuvance’s complete cap table history, request access »

Adjuvance Comparisons

HQ Location
Total Raised
Post Valuation
Developer of a biopharmaceutical platform designed to improve health and save lives through the development of vaccine a
Drug Discovery
Lincoln, NE
18 As of 2022
00000000 00 000.00


rem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor inc
Emeryville, CA
000 As of 0000
000000000 00000


laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repre
Gaithersburg, MD
0000 As of 0000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Adjuvance Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dynavax Technologies Corporation Emeryville, CA 000 00000 000000000 00000
0000000 Corporation Gaithersburg, MD 0000 00000 000000000 00000
000000000000000 00 Corporation Saint-Amand-Les-Eaux, France
You’re viewing 3 of 3 competitors. Get the full list »

Adjuvance Patents

Adjuvance Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020379738-A1 Varicella zoster Pending 05-Nov-2019 000000000
CA-3157372-A1 Varicella zoster Pending 05-Nov-2019 000000000
US-20220409721-A1 Varicella zoster Pending 05-Nov-2019 000000000
EP-4054616-A1 Varicella zoster Pending 05-Nov-2019 000000000
US-20200261571-A1 Triterpene saponin analogues Active 16-Oct-2017 A61P37/04
To view Adjuvance’s complete patent history, request access »

Adjuvance Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial